Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma-Reference-Cited by-同舟云学术

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

Published:2013-09 Issue:6 Volume:4 Page:1090-1099
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Villanueva Jessie,Infante Jeffrey R.,Krepler Clemens,Reyes-Uribe Patricia,Samanta Minu,Chen Hsin-Yi,Li Bin,Swoboda Rolf K.,Wilson Melissa,Vultur Adina,Fukunaba-Kalabis Mizuho,Wubbenhorst Bradley,Chen Thomas Y.,Liu Qin,Sproesser Katrin,DeMarini Douglas J.,Gilmer Tona M.,Martin Anne-Marie,Marmorstein Ronen,Schultz David C.,Speicher David W.,Karakousis Giorgos C.,Xu Wei,Amaravadi Ravi K.,Xu Xiaowei,Schuchter Lynn M.,Herlyn Meenhard,Nathanson Katherine L.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference25 articles.

1. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3;Abel;J. Clin. Invest.,2013

2. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance;Das Thakur;Nature,2013

3. MEK1 mutations confer resistance to MEK and B-RAF inhibition;Emery;Proc. Natl. Acad. Sci. USA,2009

4. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial;Falchook;Lancet Oncol.,2012

5. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;N. Engl. J. Med.,2012

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Susceptibility and Treatment Challenges in Melanoma;Cells;2024-08-20

2. Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches;Clinical & Experimental Metastasis;2024-06-27

3. Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma;Current Medicinal Chemistry;2023-10-19

4. Trametinib-Resistant Melanoma Cells Displaying MITFhigh/NGFRlow/IL-8low Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge;International Journal of Molecular Sciences;2023-04-26

5. Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?;Frontiers in Oncology;2023-01-09